Antonella Caivano

List of Publications by Year
in descending order

43 papers	1,287 citations	304743 22 h-index	361022 35 g-index
43 all docs	43 docs citations	43 times ranked	2089 citing authors

#	Article	IF	Citations
1	Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis Through the Release of Extracellular Vesicles. Frontiers in Oncology, 2022, 12, 824562.	2.8	5
2	Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy. Leukemia, 2021, 35, 661-678.	7.2	40
3	Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma. International Journal of Nanomedicine, 2021, Volume 16, 3141-3160.	6.7	14
4	Multiple Myeloma-Derived Extracellular Vesicles Impair Normal Hematopoiesis by Acting on Hematopoietic Stem and Progenitor Cells. Frontiers in Medicine, 2021, 8, 793040.	2.6	7
5	Advances in Azorella glabra Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization. Molecules, 2020, 25, 4890.	3.8	4
6	DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation. Stem Cell Research and Therapy, 2019, 10, 138.	5.5	12
7	An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers. Expert Review of Molecular Diagnostics, 2019, 19, 249-258.	3.1	20
8	Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells. International Journal of Molecular Sciences, 2018, 19, 3348.	4.1	17
9	Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies. Stem Cells International, 2018, 2018, 1-11.	2.5	47
10	MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2018, 19, 460.	4.1	62
11	Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia. Cell Death and Disease, 2017, 8, e2849-e2849.	6.3	32
12	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cellular Oncology (Dordrecht), 2017, 40, 483-496.	4.4	15
13	Do we need to distinguish exosomes from microvesicles in hematological malignancies?. Leukemia, 2017, 31, 2009-2010.	7.2	27
14	Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2017, 58, 1424-1432.	1.3	43
15	MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report. Cellular Oncology (Dordrecht), 2017, 40, 97-103.	4.4	65
16	Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation?. International Journal of Molecular Sciences, 2017, 18, 1022.	4.1	36
17	Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy. International Journal of Molecular Sciences, 2017, 18, 1183.	4.1	31
18	Epha3 acts as proangiogenic factor in multiple myeloma. Oncotarget, 2017, 8, 34298-34309.	1.8	23

#	Article	IF	Citations
19	A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies. Frontiers in Pharmacology, 2016, 7, 416.	3.5	8
20	P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia. Frontiers in Pharmacology, 2016, 7, 491.	3.5	27
21	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. Oncotarget, 2016, 7, 6676-6692.	1.8	86
22	Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia. Tumor Biology, 2016, 37, 217-225.	1.8	2
23	A Pyrazolo[3,4-<i>d</i>]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. Oncotarget, 2016, 7, 65171-65184.	1.8	18
24	Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. International Journal of Molecular Sciences, 2015, 16, 17514-17534.	4.1	23
25	Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells. Leukemia and Lymphoma, 2015, 56, 2458-2459.	1.3	3
26	Hit Recycling: Discovery of a Potent Carbonic Anhydrase Inhibitor by <i>in Silico</i> Target Fishing. ACS Chemical Biology, 2015, 10, 1964-1969.	3.4	19
27	High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biology, 2015, 36, 9739-9752.	1.8	159
28	A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells. Blood, 2015, 126, 3254-3254.	1.4	1
29	A HGF/cMET Autocrine Loop Is Operative in Multiple Myeloma Bone Marrow Endothelial Cells and May Represent a Novel Therapeutic Target. Clinical Cancer Research, 2014, 20, 5796-5807.	7.0	56
30	HIF-1Î± of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. Clinical Cancer Research, 2014, 20, 847-858.	7.0	54
31	High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders. Blood, 2014, 124, 2917-2917.	1.4	0
32	EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody. Blood, 2013, 122, 3211-3211.	1.4	0
33	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. International Journal of Molecular Sciences, 2012, 13, 5674-5699.	4.1	22
34	Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene, 2012, 31, 2258-2269.	5.9	31
35	Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8+ T Cells. PLoS ONE, 2012, 7, e31464.	2.5	32
36	A multimeric immunogen for the induction of immune memory to betaâ€amyloid. Immunology and Cell Biology, 2011, 89, 604-609.	2.3	17

#	Article	IF	Citations
37	Vaccination with filamentous bacteriophages targeting DECâ€205 induces DC maturation and potent antiâ€tumor Tâ€cell responses in the absence of adjuvants. European Journal of Immunology, 2011, 41, 2573-2584.	2.9	48
38	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. Clinical Cancer Research, 2011, 17, 1935-1946.	7.0	75
39	HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNÎ³ production by CD4+ T cells. Virology, 2010, 407, 296-305.	2.4	22
40	Comparative analysis of new innovative vaccine formulations based on the use of procaryotic display systems. Vaccine, 2007, 25, 1993-2000.	3.8	17
41	Induction of specific T-helper and cytolytic responses to epitopes displayed on a virus-like protein scaffold derived from the pyruvate dehydrogenase multienzyme complex. Vaccine, 2003, 21, 1502-1509.	3.8	28
42	Use of Fusion Proteins and Procaryotic Display Systems for Delivery of HIV-1 Antigens: Development of Novel Vaccines for HIV-1 Infection. Current HIV Research, 2003, 1, 441-446.	0.5	31
43	Design of cassette vectors permitting cloning of all types of human TCR variable Î± and Î² regions. Journal of Immunological Methods, 2001, 255, 125-134.	1.4	8